Key Points

• Bristol Myers Squibb maintains strong positions in oncology and neuroscience with high free cash flow generation.

• Pfizer is undergoing a major transformation by acquiring high-growth businesses in oncology and obesity care.

• Which of these pharmaceutical giants is the better buy for your portfolio heading into 2026?

• 10 stocks we like better than Bristol Myers Squibb ›

Healthcare investors often weigh the dividends and pipelines of industry titans. Are you looking for the steady cash flows of Bristol Myers Squibb (NYSE:BMY) or the ambitious transformation currently underway at Pfizer (NYSE:PFE)?

These two drugmakers are often compared because they both face upcoming patent expirations on blockbuster medications. While one focuses on refining its core strengths in specialized oncology and immunology, the other is using a massive cash pile from the pandemic era to buy its way into new high-growth therapeutic areas.

The case for Bristol Myers Squibb

Bristol-Myers Squibb develops innovative treatments for serious diseases, primarily focusing on oncology, hematology, and neuroscience. In its latest annual report, filed with the SEC, the company emphasized its leadership in cancer therapy. It maintains global strategic alliances with Merck (NYSE:MRK) and Zai Lab (NASDAQ:ZLAB) for various products. Recently, the company ended its manufacturing partnership with Cellares to streamline production. It reaches patients through direct sales channels and partnerships with global distributors.

In FY 2025, revenue reached nearly $48.2 billion, representing a slight decline of approximately 0.2% compared to the previous year. Net income for the period was close to $7.1 billion. This resulted in a net margin of 14.6%, which reflects the percentage of revenue remaining after all expenses are paid. This performance marks a significant recovery from the previous fiscal year when the company reported a net loss.

As of its December 2025 balance sheet, the debt-to-equity ratio was 2.6x. This number shows that for every dollar of shareholder equity, the company carries $2.60 in total debt. The current ratio stands at approximately 1.3x, measuring its ability to cover short-term liabilities with assets easily converted to cash. Free cash flow, the money left after paying for operating activities and capital equipment, was roughly $12.8 billion.

The case for Pfizer

Pfizer applies science to develop medicines and vaccines across approximately 200 countries. It is a prominent name among pharmaceutical stocks as it pivots toward high-growth oncology and obesity markets. This strategy is supported by recent acquisitions of Seagen and Metsera. The company sells its products through extensive distribution networks that include wholesalers and large pharmacy chains.

In FY 2025, Pfizer reported revenue of roughly $62.6 billion, a decrease of nearly 1.6% from the prior year. Net income for the fiscal year reached approximately $7.8 billion. The company reported a net margin of 12.4%. This indicates the portion of total sales that turned into actual profit.

As of the December 2025 balance sheet, the debt-to-equity ratio was nearly 0.8x. This suggests a more conservative capital structure compared to many large peers. The current ratio was approximately 1.2x, which indicates the company has enough short-term assets to meet its immediate financial obligations. Free cash flow was close to $9.1 billion, providing the financial flexibility needed for research and development.

Risk profile comparison

Bristol Myers Squibb faces intense pricing pressure from government-mandated controls and the Inflation Reduction Act. The company also deals with significant revenue risks as major products lose patent exclusivity and face generic competition. Ongoing litigation adds further uncertainty, including a $6.7 billion legal challenge and a lawsuit from Cytokinetics (NASDAQ:CYTK). Complex manufacturing requirements for cell therapies also create potential supply chain bottlenecks.

Pfizer also navigates substantial legal overhangs, recently settling thousands of federal lawsuits regarding its contraceptive products. The company faces a revenue cliff as sales of COVID-19 related products decline and other blockbusters lose patent protection. To combat this, it must successfully execute its oncology and obesity pipelines. It also faces ongoing patent litigation from firms like Hikma Pharmaceuticals (OTC:HKMPF) as it defends its market share.

Valuation comparison

While both companies trade at conservative Forward P/E and P/S ratio levels, Pfizer offers a slightly lower revenue multiple compared to its peer.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with Pfizer, though Bristol Myers Squibb is a more compelling near-term bet than its beaten-down stock price implies. BMS just raised its full-year revenue outlook, newer growth brands grew at an impressive pace last quarter, and Eliquis is defying expectations with growth well above what analysts projected. For investors who want results today, BMS is delivering them.

But Pfizer is playing a longer game, and that is what makes it the more interesting pick for patient investors. Its $10 billion acquisition of Metsera puts it directly in the obesity drug race alongside Eli Lilly and Novo Nordisk. Several key clinical trial results are expected over the next 12 months, and management has committed to protecting and growing the dividend while the transformation plays out.

BMS is winning the near-term battle, but Pfizer is positioning itself for what comes after 2028, and the potential upside from its obesity pipeline alone could dwarf anything BMS has in development. For investors with a long time horizon, that kind of transformational bet is worth owning today.

Should you buy stock in Bristol Myers Squibb right now?

Before you buy stock in Bristol Myers Squibb, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $389,154!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,406,303!*

Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

*Stock Advisor returns as of September 24, 2026.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb, Cytokinetics, Eli Lilly, Merck, Novo Nordisk, and Pfizer. The Motley Fool recommends Hikma Pharmaceuticals Plc. The Motley Fool has a disclosure policy.